The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Emerging agents for Waldenström’s macroglobulinemia: non-covalent BTKis, BCL2 antagonists, & more
Neil Berinstein, MD, Sunnybrook Odette Cancer Centre, Toronto, Canada, comments on the emerging new agents for the treatment of Waldenström’s macroglobulinemia. He mentions non-covalent BTK inhibitors (BTKis), BCL2 antagonists and degraders, and bispecific antibodies. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah well right now there are a lot of new agents that are coming into play and that’s really good for patients with all lymphomas but also for Waldenstrom’s. Many of these are at the very early stages of development so they’re being tested in patients with recurrent or refractory Waldenstrom’s and I’m talking about things like non-covalent BTK inhibitors like pirtobrutinib...
Yeah well right now there are a lot of new agents that are coming into play and that’s really good for patients with all lymphomas but also for Waldenstrom’s. Many of these are at the very early stages of development so they’re being tested in patients with recurrent or refractory Waldenstrom’s and I’m talking about things like non-covalent BTK inhibitors like pirtobrutinib. I’m talking about some of the BCL2 antagonists, there’s some new BCL2 antagonists and there’s some BCL2 degraders that are coming into play for Waldenstrom and these are very relevant in particular in Waldenstrom’s. But right now they are not yet at the point where they’re being tested as first line. There’s also some bispecific antibodies which have been tested on other indolent lymphomas and actually have not yet been tested in Waldenstrom. Now all of those will eventually be tested in Waldenstrom’s and they will be eventually moved up to first line once they’re shown to be safe and have activity as we expect they will in more recurrent and refractory Waldenstrom’s.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
